Circulating Circular RNAs: Novel Biomarkers for Heart Failure

19Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Heart failure (HF) is a serious, chronic disease, causing significant ill health and high mortality worldwide. The current clinical strategies emphasize reducing the transition from a healthy to a failing heart despite the shift in the clinical goal from healing to disease prevention. Recent research advancements on noncoding RNAs (ncRNAs) have demonstrated that circular RNAs (circRNAs) are significant therapeutic targets in HF. Previous studies have highlighted the potential applicability of circRNAs in the diagnosis and treatment of diseases. However, less is known regarding the potential benefits of circRNAs as novel diagnostic and treatment biomarkers for HF. In the present study, we summarize the current developments and achievements associated with the use of circRNAs as HF biomarkers. We also discuss future research directions regarding HF diagnosis and treatment.

Cite

CITATION STYLE

APA

Sun, C., Ni, M., Song, B., & Cao, L. (2020, November 13). Circulating Circular RNAs: Novel Biomarkers for Heart Failure. Frontiers in Pharmacology. Frontiers Media S.A. https://doi.org/10.3389/fphar.2020.560537

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free